BioCentury | Oct 4, 2010
Company News

Hana Biosciences, Tekmira deal

Tekmira will receive a $5.8 million payment from Hana to reduce future milestone payments owed to Tekmira under a 2006 deal. Hana has exclusive, worldwide rights to cancer compounds Marqibo vincristine, Alocrest vinorelbine and Brakiva...
BioCentury | Nov 24, 2008
Clinical News

Optisomal topotecan: Phase I started

Hana began an open-label, U.S. Phase I trial (HBS601) of injectable Brakiva in about 50 patients. Hana licensed the compound from Tekmira in 2006. Hana Biosciences Inc. (NASDAQ:HNAB), South San Francisco, Calif. Tekmira Pharmaceuticals Corp....
BioCentury | May 21, 2007
Clinical News

Optisomal topotecan: Phase I start

Next half, HNAB hopes to begin a Phase I trial in patients. HNAB has worldwide rights to the agent from TKM. Hana Biosciences Inc. (HNAB), South San Francisco, Calif. Tekmira Pharmaceuticals Corp. (TSX:TKM), Burnaby, B.C....
BioCentury | Mar 20, 2006
Company News

Hana Biosciences, Inex deal

The companies signed a letter of intent for HBX to in-license from IEX exclusive, worldwide rights to three cancer compounds formulated with next-generation liposomal delivery technology, including Marqibo sphingosomal vincristine. IEX will receive US$11.5 million...
BioCentury | Mar 18, 2006
Company News

Hana to in-license cancer compounds

HBX signed a letter of intent to in-license from Inex (TSX:IEX) exclusive, worldwide rights to three cancer compounds formulated with next-generation liposomal delivery technology, including Marqibo sphingosomal vincristine. IEX will receive US$11.5 million up front...
BioCentury | Aug 9, 2004
Product Development

Shelf life? Not to worry

Inex Pharmaceuticals Corp. has a pipeline populated with liposome-encapsulated products, so last week's decision by GlaxoSmithKline plc to terminate a deal for INX-0076 liposomal topotecan due to manufacturing issues could raise worries. But Inex says...
BioCentury | Aug 9, 2004
Company News

Inex, GlaxoSmithKline deal

IEX said GSK will terminate the companies' deal to develop liposomal topotecan ( INX-0076 ) to treat cancer. In November 2001, the companies began preclinical testing of GSK's INX-0076 using IEX's liposomal drug delivery technology. IEX said...
BioCentury | Aug 4, 2004
Company News

GSK to end Inex topotecan deal

Inex (TSE:IEX) said GlaxoSmithKline (LSE:GSK; GSK) will terminate their deal to develop liposomal topotecan ( INX-0076 ) to treat cancer. In November 2001, the companies began preclinical testing of GSK's topotecan using IEX's liposomal drug delivery technology....
Items per page:
1 - 8 of 8